Legacy Trust lessened its position in Zoetis Inc. (NYSE:ZTS – Free Report) by 1.3% in the fourth quarter, HoldingsChannel reports. The fund owned 13,721 shares of the company’s stock after selling 181 shares during the quarter. Legacy Trust’s holdings in Zoetis were worth $2,236,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently modified their holdings of ZTS. Gries Financial LLC increased its stake in Zoetis by 0.8% during the 4th quarter. Gries Financial LLC now owns 13,918 shares of the company’s stock valued at $2,268,000 after purchasing an additional 116 shares in the last quarter. New England Research & Management Inc. increased its position in shares of Zoetis by 7.7% during the fourth quarter. New England Research & Management Inc. now owns 24,943 shares of the company’s stock worth $4,064,000 after acquiring an additional 1,775 shares in the last quarter. Summa Corp. raised its holdings in shares of Zoetis by 37.3% in the 4th quarter. Summa Corp. now owns 1,424 shares of the company’s stock worth $232,000 after acquiring an additional 387 shares during the last quarter. Baader Bank Aktiengesellschaft lifted its position in Zoetis by 20.3% in the 4th quarter. Baader Bank Aktiengesellschaft now owns 2,373 shares of the company’s stock valued at $387,000 after acquiring an additional 400 shares in the last quarter. Finally, Hanson & Doremus Investment Management boosted its stake in Zoetis by 183.8% during the 4th quarter. Hanson & Doremus Investment Management now owns 508 shares of the company’s stock valued at $83,000 after purchasing an additional 329 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on ZTS. JPMorgan Chase & Co. increased their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Stifel Nicolaus reduced their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. UBS Group began coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. Finally, Leerink Partners initiated coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective for the company. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Zoetis presently has an average rating of “Buy” and an average target price of $215.00.
Zoetis Price Performance
Zoetis stock opened at $170.33 on Thursday. The business’s 50 day simple moving average is $169.93 and its 200 day simple moving average is $179.65. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53. The company has a market cap of $76.85 billion, a price-to-earnings ratio of 32.02, a PEG ratio of 2.57 and a beta of 0.89. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.
Zoetis (NYSE:ZTS – Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the prior year, the company earned $1.36 EPS. The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. Sell-side analysts forecast that Zoetis Inc. will post 5.9 EPS for the current year.
Zoetis Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be given a $0.50 dividend. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.17%. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s payout ratio is 37.59%.
Zoetis Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Recommended Stories
- Five stocks we like better than Zoetis
- Learn Technical Analysis Skills to Master the Stock Market
- As China Tightens Rare Earth Exports, These 3 Stocks Are in Focus
- Compound Interest and Why It Matters When Investing
- Rebuilding the Empire: Can Dollar General Rally in 2025?
- What is the Nikkei 225 index?
- Coinbase Gains Momentum on App Store—What It Means for the Stock
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.